Home>>Signaling Pathways>> Chromatin/Epigenetics>> PAD>>YW3-56 (hydrochloride) (technical grade)

YW3-56 (hydrochloride) (technical grade)

Catalog No.GC48263

A PAD2 and PAD4 inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

YW3-56 (hydrochloride) (technical grade) Chemical Structure

Cas No.: 2309756-20-3

Size Price Stock Qty
500 μg
$170.00
In stock
1 mg
$321.00
In stock
5 mg
$1,103.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

YW3-56 is an inhibitor of protein arginine deiminase 2 (PAD2) and PAD4 (IC50s = 0.5-1 and 1-5 μM, respectively).1 It inhibits the growth of U2OS osteosarcoma cells (IC50 = ~2.5 μM) in a p53-dependent manner via induction of SESN2 and subsequent inhibition of mTORC1. YW3-56 (10 mg/kg) reduces tumor growth in an S-180 murine sarcoma tumor model. It also inhibits tumor growth in the 1883 MDA-MB-231 breast cancer bone metastasis mouse xenograft model.2

1.Wang, Y., Li, P., Wang, S., et al.Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activityThe Journal of Biological Chemisty287(31)25941-25952(2012) 2.Wang, S., Chen, X.A., Hu, J., et al.ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cellsMol. Cancer Ther.14(4)877-888(2015)

Reviews

Review for YW3-56 (hydrochloride) (technical grade)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for YW3-56 (hydrochloride) (technical grade)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.